FNA Tumor Sampling for CD137 Modulation: A Pilot Study

Terminated

• Conditions: Non-Hodgkin Lymphoma; Head and Neck Cancer; Head and Neck Cancers; Breast Cancer; Colorectal Adenocarcinoma
• Interventions: Procedure: FNA Biopsy

• Registration Number: NCT01114256
• Lead Sponsor: Stanford University

Brief Summary

The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2010-03
• Study First Submitted: 2010-04-23
• Study First Submitted QC: 2010-04-29
• Study First Posted: 2010-05-03
• Primary Completion: 2016-01
• Study Completion: 2016-01
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-01
• Last Update Posted: 2017-08-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Fine needle aspiration (FNA) biopsies	FNA Biopsy	Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.

Primary Outcome Measures

Name	Time	Method
evaluation of change in CD137 positive NK cells in blood & tumors in response to therapeutic moAbs	12 months

Secondary Outcome Measures

Name	Time	Method
Evaluation of activation status of CD137 positive NK cells	12 months

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States